RCM
VKTX icon

Raleigh Capital Management’s Viking Therapeutics VKTX Stock Holding History

Raleigh Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.1K Sell
489
-512
-51% -$16.5K 0.01% 348
2026
Q1 		$32.6K Buy
1,001
+56
+6% +$1.8K 0.01% 318
2025
Q4 		$33.2K Buy
945
+347
+58% +$12.3K 0.01% 315
2025
Q3 		$15.7K Buy
598
+439
+276% +$13.1K 0.01% 331
2025
Q2 		$4.21K Buy
+159
New +$4.19K ﹤0.01% 382

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Raleigh Capital Management's VKTX Position: Q2 2026 in Review

Raleigh Capital Management reduced its Viking Therapeutics (VKTX) stake by 51% in Q2 2026, selling an estimated $16.5K and leaving 489 shares worth $19.1K. The position accounts for 0.01% of the portfolio, ranked #348.

Raleigh Capital Management first reported a position in VKTX in Q2 2025 and has held it in 5 quarters since. The position peaked at $33.2K in Q4 2025. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Raleigh Capital Management held 489 shares of Viking Therapeutics worth $19.1K as of Q2 2026.
  • Raleigh Capital Management sold 512 Viking Therapeutics shares in Q2 2026, an estimated $16.5K.
  • Viking Therapeutics made up 0.01% of Raleigh Capital Management's portfolio in Q2 2026, its #348 holding.
  • Raleigh Capital Management first reported a position in Viking Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Raleigh Capital Management's Viking Therapeutics position peaked at $33.2K in Q4 2025.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Raleigh Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.